

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076

Estimated average burden

hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous Names

X None

Entity Type

[0001658247](#)

Name of Issuer

Crinetics Pharmaceuticals, Inc.

X Corporation

Limited Partnership

Limited Liability Company

General Partnership

Business Trust

Other (Specify)

Jurisdiction of Incorporation/Organization

DELAWARE

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

Crinetics Pharmaceuticals, Inc.

Street Address 1

6197 CORNERSTONE COURT, SUITE 111

Street Address 2

City

State/Province/Country

ZIP/PostalCode

Phone Number of Issuer

SAN DIEGO

CALIFORNIA

92121

858-450-6464

3. Related Persons

Last Name

First Name

Middle Name

Struthers

Richard

Scott

Street Address 1

Street Address 2

c/o Crinetics Pharmaceuticals, Inc.

6197 Cornerstone Court, Suite 111

City

State/Province/Country

ZIP/PostalCode

San Diego

CALIFORNIA

92121

Relationship: X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name

First Name

Middle Name

Freeman

Mason

Street Address 1

Street Address 2

c/o Crinetics Pharmaceuticals, Inc.

6197 Cornerstone Court, Suite 111

City

State/Province/Country

ZIP/PostalCode

San Diego

CALIFORNIA

92121

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

| Last Name  | First Name                        | Middle Name    |
|--|-----------------------------------|----------------|
| Kaldor   | Steve                             |                |
| Street Address 1   | Street Address 2                  |                |
| c/o Crinetics Pharmaceuticals, Inc.                        | 6197 Cornerstone Court, Suite 111 |                |
| City   | State/Province/Country            | ZIP/PostalCode |
| San Diego  | CALIFORNIA                        | 92121          |
| <b>Relationship:</b> Executive Officer X Director Promoter |                                   |                |

Clarification of Response (if Necessary):

---

| Last Name  | First Name                        | Middle Name    |
|--|-----------------------------------|----------------|
| Shah   | Mahendra                          |                |
| Street Address 1   | Street Address 2                  |                |
| c/o Crinetics Pharmaceuticals, Inc.                        | 6197 Cornerstone Court, Suite 111 |                |
| City   | State/Province/Country            | ZIP/PostalCode |
| San Diego  | CALIFORNIA                        | 92121          |
| <b>Relationship:</b> Executive Officer X Director Promoter |                                   |                |

Clarification of Response (if Necessary):

---

| Last Name  | First Name                        | Middle Name    |
|--|-----------------------------------|----------------|
| Wierenga   | Wendell                           |                |
| Street Address 1   | Street Address 2                  |                |
| c/o Crinetics Pharmaceuticals, Inc.                        | 6197 Cornerstone Court, Suite 111 |                |
| City   | State/Province/Country            | ZIP/PostalCode |
| San Diego  | CALIFORNIA                        | 92121          |
| <b>Relationship:</b> Executive Officer X Director Promoter |                                   |                |

Clarification of Response (if Necessary):

---

| Last Name  | First Name                        | Middle Name    |
|--|-----------------------------------|----------------|
| Betz   | Stephen                           | F.             |
| Street Address 1   | Street Address 2                  |                |
| c/o Crinetics Pharmaceuticals, Inc.                        | 6197 Cornerstone Court, Suite 111 |                |
| City   | State/Province/Country            | ZIP/PostalCode |
| San Diego  | CALIFORNIA                        | 92121          |
| <b>Relationship:</b> X Executive Officer Director Promoter |                                   |                |

Clarification of Response (if Necessary):

---

| Last Name  | First Name                        | Middle Name    |
|--|-----------------------------------|----------------|
| Zhu  | YunFei                            |                |
| Street Address 1   | Street Address 2                  |                |
| c/o Crinetics Pharmaceuticals, Inc.                        | 6197 Cornerstone Court, Suite 111 |                |
| City   | State/Province/Country            | ZIP/PostalCode |
| San Diego  | CALIFORNIA                        | 92121          |
| <b>Relationship:</b> X Executive Officer Director Promoter |                                   |                |

Clarification of Response (if Necessary):

---

#### 4. Industry Group

|                              |                  |             |
|------------------------------|------------------|-------------|
| Agriculture                  | Health Care      | Retailing   |
| Banking & Financial Services | Biotechnology    | Restaurants |
| Commercial Banking           | Health Insurance | Technology  |
| Insurance                    |                  |             |

Investing  
Investment Banking  
Pooled Investment Fund  
Is the issuer registered as an investment company under the Investment Company Act of 1940?  
Yes No  
Other Banking & Financial Services  
Business Services  
Energy  
Coal Mining  
Electric Utilities  
Energy Conservation  
Environmental Services  
Oil & Gas  
Other Energy

Hospitals & Physicians  
X Pharmaceuticals  
Other Health Care  
Manufacturing  
Real Estate  
Commercial  
Construction  
REITS & Finance  
Residential  
Other Real Estate

Computers  
Telecommunications  
Other Technology  
Travel  
Airlines & Airports  
Lodging & Conventions  
Tourism & Travel Services  
Other Travel  
Other

5. Issuer Size

| <b>Revenue Range</b>         | <b>OR</b> | <b>Aggregate Net Asset Value Range</b> |
|------------------------------|-----------|--|
| No Revenues                  |           | No Aggregate Net Asset Value           |
| \$1 - \$1,000,000            |           | \$1 - \$5,000,000                      |
| \$1,000,001 - \$5,000,000    |           | \$5,000,001 - \$25,000,000             |
| \$5,000,001 - \$25,000,000   |           | \$25,000,001 - \$50,000,000            |
| \$25,000,001 - \$100,000,000 |           | \$50,000,001 - \$100,000,000           |
| Over \$100,000,000           |           | Over \$100,000,000                     |
| X Decline to Disclose        |           | Decline to Disclose                    |
| Not Applicable               |           | Not Applicable                         |

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

|   | Investment Company Act Section 3(c) |                  |
|---|-------------------------------------|------------------|
| Rule 504(b)(1) (not (i), (ii) or (iii)) | Section 3(c)(1)                     | Section 3(c)(9)  |
| Rule 504 (b)(1)(i)                      | Section 3(c)(2)                     | Section 3(c)(10) |
| Rule 504 (b)(1)(ii)                     | Section 3(c)(3)                     | Section 3(c)(11) |
| Rule 504 (b)(1)(iii)                    | Section 3(c)(4)                     | Section 3(c)(12) |
| Rule 505                                | Section 3(c)(5)                     | Section 3(c)(13) |
| X Rule 506(b)                           | Section 3(c)(6)                     | Section 3(c)(14) |
| Rule 506(c)                             | Section 3(c)(7)                     |                  |
| Securities Act Section 4(a)(5)          |                                     |                  |

7. Type of Filing

X New Notice Date of First Sale 2015-10-30 First Sale Yet to Occur  
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? X Yes No

9. Type(s) of Securities Offered (select all that apply)

Equity  
 Debt  
 Option, Warrant or Other Right to Acquire Another Security  
 Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

Pooled Investment Fund Interests  
 Tenant-in-Common Securities  
 Mineral Property Securities  
 Other (describe)

#### 10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes  No

Clarification of Response (if Necessary):

#### 11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

#### 12. Sales Compensation

Recipient Recipient CRD Number  None  
(Associated) Broker or Dealer  None (Associated) Broker or Dealer CRD Number  None

##### Street Address 1

##### Street Address 2

City State/Province/Country ZIP/Postal Code

State(s) of Solicitation (select all that apply) All States Foreign/non-US  
Check "All States" or check individual States

#### 13. Offering and Sales Amounts

Total Offering Amount \$40,000,004 USD or Indefinite  
Total Amount Sold \$18,000,001 USD  
Total Remaining to be Sold \$22,000,003 USD or Indefinite

Clarification of Response (if Necessary):

#### 14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. \_\_\_\_\_  
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

#### 15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$0 USD Estimate  
Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

#### 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$41,446 USD Estimate

Clarification of Response (if Necessary):

Repayment of loan from executive officer to Issuer.

## Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

### Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

| <b>Issuer</b>                   | <b>Signature</b>            | <b>Name of Signer</b>   | <b>Title</b>      | <b>Date</b> |
|---------------------------------|-----------------------------|-------------------------|-------------------|-------------|
| Crinetics Pharmaceuticals, Inc. | /s/ Richard Scott Struthers | Richard Scott Struthers | President and CEO | 2015-11-13  |

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

---